STP206 regulatory update

FDA granted Orphan Drug designation to STP-206 from Sigma-Tau to prevent necrotizing enterocolitis in premature infants with a birth weight of <=1.5 kg. STP-206 is in a Phase Ib/IIa trial for the indi...